Your session is about to expire
← Back to Search
Radiation Therapy
Dose Escalated IMRT for Prostate Cancer
Phase 1 & 2
Waitlist Available
Led By Andrew Bayley, MD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after all patients have completed study intervention
Awards & highlights
Study Summary
This trial is testing a new, more intense radiation therapy regimen for high-risk prostate cancer patients, to see if it is feasible and has fewer side effects than current treatments.
Eligible Conditions
- Prostate Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ after all patients have completed study intervention
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after all patients have completed study intervention
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Determine the feasibility and late toxicity of dose escalated radiation therapy to the pelvic lymph nodes and prostate and seminal vesicles in the treatment of high risk prostate cancer.
Secondary outcome measures
acute toxicity of therapy;prostate motion when pelvic radiotherapy is delivered;treatment time required to deliver IMRT to the pelvic lymph nodes, prostate and seminal vesicles
Trial Design
1Treatment groups
Experimental Treatment
Group I: IMRT in prostate cancerExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dose Escalated IMRT
2005
Completed Phase 2
~90
Find a Location
Who is running the clinical trial?
University Health Network, TorontoLead Sponsor
1,468 Previous Clinical Trials
484,409 Total Patients Enrolled
64 Trials studying Prostate Cancer
15,400 Patients Enrolled for Prostate Cancer
Andrew Bayley, MDPrincipal InvestigatorUniversity Health Network, Princess Margaret Hospital
3 Previous Clinical Trials
105 Total Patients Enrolled
Tara Rosewell, MDPrincipal InvestigatorUniversity Health Network, Princess Margaret Hospital
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have had or currently have cancer, except for non-melanoma skin cancer, within the past 5 years of being diagnosed with prostate cancer.You have a history of inflammatory bowel disease or any other condition that makes radical radiation therapy unsafe for you.You have had surgery for colorectal issues in the past.You have an advanced stage of cancer that has spread beyond its original site (Stage III or IV).
Research Study Groups:
This trial has the following groups:- Group 1: IMRT in prostate cancer
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any remaining opportunities for individuals to partake in this medical experiment?
"As per clinicaltrials.gov, this trial is not currently accepting candidates; the study was first posted in November 1st 2005 and last revised on April 7th 2022. However, there are an abundance of opportunities as 780 other medical studies actively need participants."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger